Defunct Company
Total Trials
6
As Lead Sponsor
As Collaborator
0
Total Enrollment
463
NCT01748838
Phase 1 Study Assessing the Safety and Tolerability of CTX-4430
Phase: Phase 1
Role: Lead Sponsor
Start: Dec 31, 2012
Completion: Sep 30, 2013
NCT01944735
Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 in Cystic Fibrosis Patients
Start: Sep 30, 2013
Completion: Nov 30, 2014
NCT02233244
Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of CTX 4430 and Midazolam
Start: Sep 30, 2014
Completion: Oct 31, 2014
NCT02385760
CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris
Phase: Phase 2
Start: Apr 30, 2015
Completion: Aug 31, 2016
NCT02443688
EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients
Start: Oct 30, 2015
Completion: May 16, 2018
NCT03964558
Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Acebilustat (CTX-4430)
Start: Apr 1, 2019
Completion: Apr 14, 2019